IMMEDIATELY AFTER TREATMENT

Immediately after a BPT treatment, a “flushing” of the face normally occurs. This indicates that an additional amount of oxygen has been introduced into the blood stream. A slight rise in temperature may also occur, which is the body’s natural reaction when the immune system is stimulated. The stimulated immune system continues its activity for hours and sometimes days after a treatment has been performed.


NO ADVERSE REACTIONS

Historically, there has been a complete absence of harmful effects from BPT, either immediate or delayed when BPT is used properly. This has allowed clinical investigators to use this procedure over a period of more than twenty years on a single patient.


MILD FLU LIKE SYMPTOMS

German physicians have performed hundreds of thousands of BPT treatments and never reported incidents of toxicity other than a mild Herxheimer reaction that occurs within the first 24 hours. The reaction is caused by the rapid death of large numbers of infectious organisms. The symptoms are characterized by chills and a rise in temperature similar to “flu-like” symptoms. These symptoms can occur with any type of treatment including antibiotics.


INCREASED DRUG EFFECTS

Sulpha drugs should be allowed a “washout” period of 7-10 days before BPT is given and not used for 7 days after treatment.


INCREASED REACTION

In a few chronic diseases, approximately 50% of individuals with bronchial asthma, nasal sinusitis and chronic rheumatic disease may have an aggravation to the pre-existing symptoms, which is usually no more severe than any previous severe responses. This is especially true following the first application of BPT, much less after a second treatment and rarely after a third treatment.

 
The material appearing on this Website is intended for informational and/or educational purposes only and has not been evaluated by the Food and Drug Administration. It is not intended to diagnose or treat any disease or person and should not be used as a substitute for professional medical advice.